258 related articles for article (PubMed ID: 16912307)
1. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense.
Pampin M; Simonin Y; Blondel B; Percherancier Y; Chelbi-Alix MK
J Virol; 2006 Sep; 80(17):8582-92. PubMed ID: 16912307
[TBL] [Abstract][Full Text] [Related]
2. Role and fate of PML nuclear bodies in response to interferon and viral infections.
Regad T; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7274-86. PubMed ID: 11704856
[TBL] [Abstract][Full Text] [Related]
3. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
5. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.
Peche LY; Scolz M; Ladelfa MF; Monte M; Schneider C
Cell Death Differ; 2012 Jun; 19(6):926-36. PubMed ID: 22117195
[TBL] [Abstract][Full Text] [Related]
6. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.
Komura N; Asakawa M; Umezawa K; Segawa K
Exp Cell Res; 2007 Aug; 313(13):2753-65. PubMed ID: 17585903
[TBL] [Abstract][Full Text] [Related]
8. SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
El McHichi B; Regad T; Maroui MA; Rodriguez MS; Aminev A; Gerbaud S; Escriou N; Dianoux L; Chelbi-Alix MK
J Virol; 2010 Nov; 84(22):11634-45. PubMed ID: 20826694
[TBL] [Abstract][Full Text] [Related]
9. PML regulates p53 stability by sequestering Mdm2 to the nucleolus.
Bernardi R; Scaglioni PP; Bergmann S; Horn HF; Vousden KH; Pandolfi PP
Nat Cell Biol; 2004 Jul; 6(7):665-72. PubMed ID: 15195100
[TBL] [Abstract][Full Text] [Related]
10. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.
Bøe SO; Haave M; Jul-Larsen A; Grudic A; Bjerkvig R; Lønning PE
J Cell Sci; 2006 Aug; 119(Pt 16):3284-95. PubMed ID: 16868026
[TBL] [Abstract][Full Text] [Related]
11. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
12. PML nuclear bodies and apoptosis.
Takahashi Y; Lallemand-Breitenbach V; Zhu J; de Thé H
Oncogene; 2004 Apr; 23(16):2819-24. PubMed ID: 15077145
[TBL] [Abstract][Full Text] [Related]
13. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication.
Jul-Larsen A; Visted T; Karlsen BO; Rinaldo CH; Bjerkvig R; Lønning PE; Bøe SO
Exp Cell Res; 2004 Aug; 298(1):58-73. PubMed ID: 15242762
[TBL] [Abstract][Full Text] [Related]
14. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
15. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
[TBL] [Abstract][Full Text] [Related]
16. PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.
Ivanschitz L; Takahashi Y; Jollivet F; Ayrault O; Le Bras M; de Thé H
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):14278-83. PubMed ID: 26578773
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
18. Regulation of p53 activity in nuclear bodies by a specific PML isoform.
Fogal V; Gostissa M; Sandy P; Zacchi P; Sternsdorf T; Jensen K; Pandolfi PP; Will H; Schneider C; Del Sal G
EMBO J; 2000 Nov; 19(22):6185-95. PubMed ID: 11080164
[TBL] [Abstract][Full Text] [Related]
19. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
Shen H; Maki CG
J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
[TBL] [Abstract][Full Text] [Related]
20. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
